Squarepoint’s GSK GSK Stock Holding History

Squarepoint’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.16M	Sell	60,200 -19,500	-24%	-$1.03M	﹤0.01%	1970
2026 Q1	$4.4M	Sell	79,700 -53,300	-40%	-$2.89M	0.01%	1600
2025 Q4	$6.52M	Buy	133,000 +82,000	+161%	+$3.82M	0.01%	1297
2025 Q3	$2.2M	Sell	51,000 -30,400	-37%	-$1.19M	﹤0.01%	2015
2025 Q2	$3.13M	Buy	81,400 +64,900	+393%	+$2.48M	﹤0.01%	1776
2025 Q1	$639K	Sell	16,500 -95,500	-85%	-$3.5M	﹤0.01%	3066
2024 Q4	$3.79M	Buy	+112,000	New	+$4.03M	﹤0.01%	1860
2024 Q3	–	Sell	-23,700	Closed	-$912K	–	4329
2024 Q2	$912K	Buy	+23,700	New	+$997K	﹤0.01%	2624

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Squarepoint's GSK Position: Q2 2026 in Review

Squarepoint reduced its GSK (GSK) stake by 7.6% in Q2 2026, selling an estimated $251K and leaving 57,963 shares worth $3.04M. The position accounts for ﹤0.01% of the portfolio, ranked #1997.

Squarepoint first reported a position in GSK in Q1 2019 and has held it in 25 quarters since. The position peaked at $9.28M in Q3 2022. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Squarepoint held 57,963 shares of GSK worth $3.04M as of Q2 2026.
Squarepoint sold 4,748 GSK shares in Q2 2026, an estimated $251K.
GSK made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #1997 holding.
Squarepoint first reported a position in GSK in Q1 2019 and has held it in 25 quarters since.
Squarepoint's GSK position peaked at $9.28M in Q3 2022.
1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.